0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Hopping Mad Over Drug Company Product Hopping [Forbes]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Forbes
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Corrected, Jan. 15, 2026: This story originally stated that the state of California had sued Gilead. It has been updated to note that many individual plaintiffs sued the company. A group of plaintiffs is suing Gilead Sciences in the Superior Court of California for the County of San Francisco over its delay of an HIV drug, a move that critics of the pharmaceutical industry call “product hopping.” Regardless of how the lawsuit comes out, the company's actions strike me as deeply immoral and ought to leave all of us hopping mad. Here's what we know. In the late 1990s, Gilead was investigating two HIV drugs each with the same active ingredient: tenofovir. One of those drugs, eventually known as Stribild, received FDA approval in 2012. It was effective against HIV in early trials but had lots of side effects. A second drug looked more promising; it combined the active ingredient with other chemicals that significantly reduced the risk of side effects. The company recognized that th [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

Hopping Mad Over Drug Company Product Hopping [Forbes]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Forbes
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Corrected, Jan. 15, 2026: This story originally stated that the state of California had sued Gilead. It has been updated to note that many individual plaintiffs sued the company. A group of plaintiffs is suing Gilead Sciences in the Superior Court of California for the County of San Francisco over its delay of an HIV drug, a move that critics of the pharmaceutical industry call “product hopping.” Regardless of how the lawsuit comes out, the company's actions strike me as deeply immoral and ought to leave all of us hopping mad. Here's what we know. In the late 1990s, Gilead was investigating two HIV drugs each with the same active ingredient: tenofovir. One of those drugs, eventually known as Stribild, received FDA approval in 2012. It was effective against HIV in early trials but had lots of side effects. A second drug looked more promising; it combined the active ingredient with other chemicals that significantly reduced the risk of side effects. The company recognized that th [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS